Oxigene +131.4% AH on positive Phase 2 results

A Phase 2 trial of Oxigene's (OXGN) Zybrestat ovarian cancer drug (used in combination with Roche's Avastin) "met its primary endpoint of a statistically significant increase in progression-free survival." (PR)

Oxigene expects full study results to be "submitted for presentation at a future scientific meeting."

CEO Peter Langecker: "Zybrestat is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need."

Comments (2)
  • TruffelPig
    , contributor
    Comments (4208) | Send Message
    What I think is interesting is that this is the first time a combo of anti-angiogenesis drug and vascular disruption is used. No typical cytotoxic per se. NCI sponsored this.
    11 Mar 2014, 08:50 PM Reply Like
  • Chemist357
    , contributor
    Comments (280) | Send Message
    Not sure what to make of the secondary objectives though:


    "Patients receiving the combination of ZYBRESTAT and Avastin achieved a higher objective response rate, which was not statistically significant. All patients will continue to be followed for overall survival. Consistent with prior clinical experience with ZYBRESTAT, patients in the combination arm experienced a higher incidence of hypertension compared to the control arm"


    Don't get me wrong a phase III should clear these questions - hypertension normal to stage I or normal to hypertensive emergency? Will look forward to the data release.
    11 Mar 2014, 10:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs